Terms: = Breast cancer AND ACVR1, SKR1, 90, ENSG00000115170, Q04771, ACVRLK2, FOP, ALK2, ACTRI AND Treatment
5575 results:
1. A dosiomics model for prediction of radiation-induced acute skin toxicity in breast cancer patients: machine learning-based study for a closed bore linac.
Saadatmand P; Mahdavi SR; Nikoofar A; Jazaeri SZ; Ramandi FL; Esmaili G; Vejdani S
Eur J Med Res; 2024 May; 29(1):282. PubMed ID: 38735974
[TBL] [Abstract] [Full Text] [Related]
2. Implementation of a clinical breast exam and referral program in a rural district of Pakistan.
Martins RS; Arif A; Yameen S; Noordin S; Masroor T; Muhammad S; Channa M; Soofi SB; Sattar AK
BMC Health Serv Res; 2024 May; 24(1):616. PubMed ID: 38730486
[TBL] [Abstract] [Full Text] [Related]
3. Comparison of anthracycline-containing and anthracycline-free regimens in neoadjuvant HER-2 positive breast cancer treatment.
Bardakci M; Karakas H; Bayram D; Avci N; Kitapli S; Ozen M; Aslan F; Koseoglu C; Kadioglu A; Onur ID; Sakalar T; Buyuksimsek M; Alkan A; Ergun Y; Kaya AO; Bilgin B; Yalcin B
Sci Rep; 2024 May; 14(1):10632. PubMed ID: 38724585
[TBL] [Abstract] [Full Text] [Related]
4. Preexisting Diabetes and breast cancer treatment Among Low-Income Women.
Bekele BB; Lian M; Schmaltz C; Greever-Rice T; Shrestha P; Liu Y
JAMA Netw Open; 2024 May; 7(5):e249548. PubMed ID: 38717774
[TBL] [Abstract] [Full Text] [Related]
5. Acupuncture for the treatment of the pain-fatigue-sleep disturbance-numbness/tingling symptom cluster in breast cancer survivors: a feasibility trial.
Kwon KK; Lacey J; Kerin-Ayres K; Heller G; Grant S
Support Care Cancer; 2024 May; 32(6):332. PubMed ID: 38713422
[TBL] [Abstract] [Full Text] [Related]
6. MCT4 knockdown by tumor microenvironment-responsive nanoparticles remodels the cytokine profile and eradicates aggressive breast cancer cells.
Abdellatif AAH; Bouazzaoui A; Tawfeek HM; Younis MA
Colloids Surf B Biointerfaces; 2024 Jun; 238():113930. PubMed ID: 38692174
[TBL] [Abstract] [Full Text] [Related]
7. A Comparative Analysis of Implant-sparing Plan
Onal C; Bozca R; Dolek Y; Elmali A; Guler OC
In Vivo; 2024; 38(3):1412-1420. PubMed ID: 38688603
[TBL] [Abstract] [Full Text] [Related]
8. True Donor Cell Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: Diagnostic and Therapeutic Considerations-Brief Report.
Hoffmann M; Banz Y; Halter J; Schoumans J; Tchinda J; Bacher U; Pabst T
Curr Oncol; 2024 Apr; 31(4):2067-2075. PubMed ID: 38668056
[TBL] [Abstract] [Full Text] [Related]
9. A randomized clinical trial: Efficacy of group-based acceptance and commitment therapy program for breast cancer patients with high fear of progression.
Hassani Alimolk F; McDonald FEJ; Asghari-Jafarabadi M; Ahmadi F; Zenoozian S; Lashkari M; Patterson P
Psychooncology; 2024 Apr; 33(4):e6339. PubMed ID: 38653573
[TBL] [Abstract] [Full Text] [Related]
10. NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer.
Jacobs SA; Wang Y; Abraham J; Feng H; Montero AJ; Lipchik C; Finnigan M; Jankowitz RC; Salkeni MA; Maley SK; Puhalla SL; Piette F; Quinn K; Chang K; Nagy RJ; Allegra CJ; Vehec K; Wolmark N; Lucas PC; Srinivasan A; Pogue-Geile KL
Breast Cancer Res; 2024 Apr; 26(1):69. PubMed ID: 38650031
[TBL] [Abstract] [Full Text] [Related]
11. Hypertension Severity and Declines in Left Ventricular Ejection Fraction Among Women Receiving Adjuvant Chemotherapy for breast cancer (WF-97415 UPBEAT).
Garg R; D'Agostino RB; O'Connell N; Lesser GJ; Salloum FN; Hines AL; Meléndez GC; Jordan JH; Ky B; Wagner LI; Sutton AL; Bottinor W; Olson KC; Ladd AC; Hundley WG;
Hypertension; 2024 Jun; 81(6):1365-1373. PubMed ID: 38634292
[TBL] [Abstract] [Full Text] [Related]
12. B7-H3 Expression in breast cancer and Brain Metastasis.
Joshi V; Beecher K; Lim M; Stacey A; Feng Y; Jat PS; Duijf PHG; Simpson PT; Lakhani SR; McCart Reed AE
Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612786
[TBL] [Abstract] [Full Text] [Related]
13. Active substance and mechanisms of Actinidia chinensis Planch for the treatment of breast cancer was explored based on network pharmacology and in silico study.
Xu Y; Yang J; Han X; Gan C; Wei X
Medicine (Baltimore); 2024 Apr; 103(15):e37829. PubMed ID: 38608062
[TBL] [Abstract] [Full Text] [Related]
14. Impact of chrono-radiotherapy on the prognosis and treatment-related toxicity in patients with locally advanced nasopharyngeal carcinoma: A multicenter propensity-matched study.
Lin J; Lin X; Zheng R; Lin K; Khan M; Huang X; Tian Y; Wang B; Xu B; Yuan Y; Huang Z
Chronobiol Int; 2024 Apr; 41(4):587-597. PubMed ID: 38606920
[TBL] [Abstract] [Full Text] [Related]
15. Phase II Study of Erdafitinib in Patients With Tumors With
Gong J; Mita AC; Wei Z; Cheng HH; Mitchell EP; Wright JJ; Ivy SP; Wang V; Gray RC; McShane LM; Rubinstein LV; Patton DR; Williams PM; Hamilton SR; Alva AS; Tricoli JV; Conley BA; Arteaga CL; Harris LN; O'Dwyer PJ; Chen AP; Flaherty KT
JCO Precis Oncol; 2024 Apr; 8():e2300406. PubMed ID: 38603651
[TBL] [Abstract] [Full Text] [Related]
16. treatment Outcomes of Stereotactic Ablative Body Radiotherapy on Extra-cranial Oligometastatic and Oligoprogressive breast cancer: Mature Results from a Single Institution Experience.
Armstrong S; Makris A; Belessiotis-Richards K; Abdul-Latif M; Ostler P; Shah N; Miles D; Tsang YM
Clin Oncol (R Coll Radiol); 2024 Jun; 36(6):362-369. PubMed ID: 38575431
[TBL] [Abstract] [Full Text] [Related]
17. Geriatric assessment-identified impairments and frailty in adults with cancer younger than 65: An opportunity to optimize oncology care.
Pergolotti M; Wood KC; Hidde M; Kendig TD; Ronnen EA; Giri S; Williams GR
J Geriatr Oncol; 2024 May; 15(4):101751. PubMed ID: 38569461
[TBL] [Abstract] [Full Text] [Related]
18. Comparison of neoadjuvant chemotherapy response and prognosis between HR-low/HER2-negative BC and TNBC: an exploratory real-world multicentre cohort study.
Peng J; Hong Y; Chen Q; Xu F; Zhang D; Yao J; Zou Q; Yuan L; Li L; Long Q; Liao L; Liu M; Liu X; Wang S; Yi W
Front Endocrinol (Lausanne); 2024; 15():1347762. PubMed ID: 38567311
[TBL] [Abstract] [Full Text] [Related]
19. Tumor-Infiltrating Lymphocytes in Triple-Negative breast cancer.
Leon-Ferre RA; Jonas SF; Salgado R; Loi S; de Jong V; Carter JM; Nielsen TO; Leung S; Riaz N; Chia S; Jules-Clément G; Curigliano G; Criscitiello C; Cockenpot V; Lambertini M; Suman VJ; Linderholm B; Martens JWM; van Deurzen CHM; Timmermans AM; Shimoi T; Yazaki S; Yoshida M; Kim SB; Lee HJ; Dieci MV; Bataillon G; Vincent-Salomon A; André F; Kok M; Linn SC; Goetz MP; Michiels S;
JAMA; 2024 Apr; 331(13):1135-1144. PubMed ID: 38563834
[TBL] [Abstract] [Full Text] [Related]
20. Gedatolisib in combination with palbociclib and endocrine therapy in women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the dose expansion groups of an open-label, phase 1b study.
Layman RM; Han HS; Rugo HS; Stringer-Reasor EM; Specht JM; Dees EC; Kabos P; Suzuki S; Mutka SC; Sullivan BF; Gorbatchevsky I; Wesolowski R
Lancet Oncol; 2024 Apr; 25(4):474-487. PubMed ID: 38547892
[TBL] [Abstract] [Full Text] [Related]
[Next]
